Resveratrol Promotes Regression of Renal Carcinoma Cells Via a Renin-angiotensin System Suppression-dependent Mechanism

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 Mar 31

PMID 28356937

Citations 5

Authors

Jianchang Li

Mingning Qiu

Lieqian Chen

Lei Liu

Guobin Tan

Jianjun Liu

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to investigate the effect of resveratrol on renal carcinoma cells and explore possible renin-angiotensin system-associated mechanisms. Subsequent to resveratrol treatment, the cell viability, apoptosis rate, cytotoxicity levels, caspase 3/7 activity and the levels of angiotensin II (AngII), AngII type 1 receptor (AT1R), vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) were evaluated in renal carcinoma cells. The effects of AngII, AT1R, VEGF and COX-2 on resveratrol-induced cell growth inhibition and apoptosis were also examined. The results indicated that resveratrol treatment may suppress growth, induce apoptosis, and decrease AngII, AT1R, VEGF and COX-2 levels in renal carcinoma ACHN and A498 cells. In addition, resveratrol-induced cell growth suppression and apoptosis were reversed when co-culturing with AT1R or VEGF. Thus, resveratrol may suppress renal carcinoma cell proliferation and induce apoptosis via an AT1R/VEGF pathway.

Citing Articles

Targeting Gut Microbiota with Probiotics and Phenolic Compounds in the Treatment of Atherosclerosis: A Comprehensive Review.

Cruz Neto J, de Luna Freire M, de Albuquerque Lemos D, Ribeiro Alves R, de Farias Cardoso E, de Moura Balarini C Foods. 2024; 13(18).

PMID: 39335815 PMC: 11431284. DOI: 10.3390/foods13182886.

Kidney Cancer Integrative Oncology: Possible Options for Care.

Mathis S, Sierpina V Curr Oncol Rep. 2023; 25(9):1071-1080.

PMID: 37466849 DOI: 10.1007/s11912-023-01437-x.

Resveratrol, Epigallocatechin Gallate and Curcumin for Cancer Therapy: Challenges from Their Pro-Apoptotic Properties.

Chimento A, DAmico M, De Luca A, Conforti F, Pezzi V, De Amicis F Life (Basel). 2023; 13(2).

PMID: 36836619 PMC: 9962739. DOI: 10.3390/life13020261.

Gut Microbiota-Derived Resveratrol Metabolites, Dihydroresveratrol and Lunularin, Significantly Contribute to the Biological Activities of Resveratrol.

Li F, Han Y, Wu X, Cao X, Gao Z, Sun Y Front Nutr. 2022; 9:912591.

PMID: 35634412 PMC: 9131081. DOI: 10.3389/fnut.2022.912591.

Polyphenols and Their Metabolites in Renal Diseases: An Overview.

Guerreiro I, Ferreira-Pego C, Carregosa D, Santos C, Menezes R, Fernandes A Foods. 2022; 11(7).

PMID: 35407148 PMC: 8997953. DOI: 10.3390/foods11071060.

References

Carter L, DOrazio J, Pearson K . Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer. 2014; 21(3):R209-25. PMC: 4013237. DOI: 10.1530/ERC-13-0171. View

Chen Y, Chen Y, Lin Y, Hu H, Liao H . Resveratrol inhibits alpha-melanocyte-stimulating hormone signaling, viability, and invasiveness in melanoma cells. Evid Based Complement Alternat Med. 2013; 2013:632121. PMC: 3676971. DOI: 10.1155/2013/632121. View

Fraser S, Peters A, Fleming-Jones S, Mukhey D, Djamgoz M . Resveratrol: inhibitory effects on metastatic cell behaviors and voltage-gated Na⁺ channel activity in rat prostate cancer in vitro. Nutr Cancer. 2014; 66(6):1047-58. DOI: 10.1080/01635581.2014.939291. View

Schmedtje Jr J, Ji Y, Liu W, DuBois R, Runge M . Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem. 1997; 272(1):601-8. DOI: 10.1074/jbc.272.1.601. View

Ndiaye M, Kumar R, Ahmad N . Resveratrol in cancer management: where are we and where we go from here?. Ann N Y Acad Sci. 2011; 1215:144-9. DOI: 10.1111/j.1749-6632.2010.05851.x. View

Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H . Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers. Cancer Biol Ther. 2014; 15(8):975-81. PMC: 4119082. DOI: 10.4161/cbt.29187. View

Wu M, Li H, Yu L, Chen X, Kong Q, Song X . Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS One. 2014; 9(2):e89806. PMC: 3934942. DOI: 10.1371/journal.pone.0089806. View

Aggarwal B, Bhardwaj A, Aggarwal R, Seeram N, Shishodia S, Takada Y . Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004; 24(5A):2783-840. View

Bradshaw A, Wickremesekera A, Brasch H, Chibnall A, Davis P, Tan S . Glioblastoma Multiforme Cancer Stem Cells Express Components of the Renin-Angiotensin System. Front Surg. 2016; 3:51. PMC: 5037176. DOI: 10.3389/fsurg.2016.00051. View

10.

Mikula-Pietrasik J, Sosinska P, Ksiazek K . Resveratrol inhibits ovarian cancer cell adhesion to peritoneal mesothelium in vitro by modulating the production of α5β1 integrins and hyaluronic acid. Gynecol Oncol. 2014; 134(3):624-30. DOI: 10.1016/j.ygyno.2014.06.022. View

11.

Fan L, Feng Y, Wan H, Ni L, Qian Y, Guo Y . Hypoxia induces dysregulation of local renin-angiotensin system in mouse Lewis lung carcinoma cells. Genet Mol Res. 2014; 13(4):10562-73. DOI: 10.4238/2014.December.12.19. View

12.

Childers W . Interactions of the renin-angiotensin system in colorectal cancer and metastasis. Int J Colorectal Dis. 2015; 30(6):749-52. DOI: 10.1007/s00384-014-2118-1. View

13.

Hoellen F, Waldmann A, Banz-Jansen C, Rody A, Heide M, Koster F . Expression of cyclooxygenase-2 in cervical cancer is associated with lymphovascular invasion. Oncol Lett. 2016; 12(4):2351-2356. PMC: 5038214. DOI: 10.3892/ol.2016.4925. View

14.

Miyajima A, Yazawa S, Kosaka T, Tanaka N, Shirotake S, Mizuno R . Prognostic Impact of Renin-Angiotensin System Blockade on Renal Cell Carcinoma After Surgery. Ann Surg Oncol. 2015; 22(11):3751-9. DOI: 10.1245/s10434-015-4436-0. View

15.

Yoshida T, Kinoshita H, Fukui K, Matsuzaki T, Yoshida K, Mishima T . Prognostic Impact of Renin-Angiotensin Inhibitors in Patients with Bladder Cancer Undergoing Radical Cystectomy. Ann Surg Oncol. 2016; 24(3):823-831. DOI: 10.1245/s10434-016-5534-3. View

16.

Miyajima A, Kikuchi E, Kosaka T, Oya M . Angiotensin II Type 1 Receptor Antagonist as an Angiogenic Inhibitor in Urogenital Cancer. Rev Recent Clin Trials. 2009; 4(2):75-8. DOI: 10.2174/157488709788185996. View

17.

He W, Zhang M, Zhao M, Davis L, Blackwell T, Yull F . Increased dietary sodium induces COX2 expression by activating NFκB in renal medullary interstitial cells. Pflugers Arch. 2013; 466(2):357-367. PMC: 3946848. DOI: 10.1007/s00424-013-1328-7. View

18.

Shi Y, Yang S, Troup S, Lu X, Callaghan S, Park D . Resveratrol induces apoptosis in breast cancer cells by E2F1-mediated up-regulation of ASPP1. Oncol Rep. 2011; 25(6):1713-9. DOI: 10.3892/or.2011.1248. View

19.

Subbaramaiah K, Dannenberg A . Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 2003; 24(2):96-102. DOI: 10.1016/S0165-6147(02)00043-3. View

20.

de Haas S, Delmar P, Bansal A, Moisse M, Miles D, Leighl N . Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis. 2014; 17(4):909-20. DOI: 10.1007/s10456-014-9438-1. View